Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Juno Therapeutics.

Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical Experience

Release Date: January 31, 2018
Expiration Date: January 31, 2019
Media: Internet - based


Activity Overview

Chimeric antigen receptor (CAR) T cells has recently emerged as a novel therapeutic approach, yielding complete responses even in heavily pretreated patients with leukemia, lymphoma, and myeloma. Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical Experience features case-based discussion on the application of CAR T-cell therapy in various hematologic malignancies. Interactive clinical vignettes are followed by short video interviews with leading oncology experts and short summaries of clinical data related to these clinical settings. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Juno Therapeutics.

CME Activity Table of Contents

  • Module 1. CAR T Cells: Introduction
  • Module 2. A Patient With Relapsed DLBCL
  • Module 3. A Patient With Relapsed, B-Cell Precursor ALL
  • Module 4. A Patient With Relapsed CLL
  • Module 5. A Patient With Relapsed MM

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This activity is intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the use of CAR T-cell therapy for patients with hematologic malignancies. Fellows, investigators, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with hematologic malignancies are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Describe the structure and function of the CAR and the mechanism of action of CAR T cells in lymphoma
  • Review clinical trial evidence, with a focus on non-Hodgkin lymphoma and chronic lymphocytic leukemia, and describe where CAR T-cell therapies might fit into the treatment landscape
  • Review clinical trial evidence in other lymphoid malignancies, and describe where CAR T-cell therapy might fit into that treatment landscape
  • Identify and discuss the management of toxicities of CAR T-cell therapies

Faculty, Staff, and Planners' Disclosures


David G. Maloney, MD, PhD
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor of Medicine, Division of Oncology
University of Washington
Seattle, WA

Disclosure: Grant/Research Report: Juno Therapeutics, paid to institution; Consultant: Celgene, F. Hoffmann-La Roche, Gilead Sciences, Kite Pharma

Jeremy S. Abramson, MD
Assistant Professor of Medicine
Harvard Medical School
Director, Lymphoma Program, Cancer Center
Massachusetts General Hospital
Boston, MA

Disclosure: Consultant: Celgene, Genentech, Gilead Sciences, Novartis, Seattle Genetics

Stephen J. Schuster, MD
Director, Lymphoma Program
Director, Lymphoma Translational Research
Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research
Penn Medicine
Philadelphia, PA

Disclosure: Grant/Research Report: Novartis, Celgene, Merck, Adaptive Biotechnologies, Janssen, ImmunoGen, Pharmacyclics, Gilead Sciences, Bristol-Meyers Squibb, Incyte, Genentech; Consultant: Merck, Celgene, Gilead Sciences, Nordic Nanovector, Novartis, Genentech, Seattle Genetics

James N. Kochenderfer, MD
Investigator, Experimental Transplantation and Immunology Branch
National Cancer Institute (NCI) Center for Cancer Research
Bethesda, MD

Disclosure: Principal Investigator of research agreements between NCI and both Kite Pharma and Bluebird Bio

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By